Scilex Holding Business Summary

Scilex Holding Co (SCLX) is a commercial-stage biopharmaceutical company that generates revenue through the sale and licensing of non-opioid pain management therapies. The company’s business model is centered on the acquisition, clinical development, and commercialization of targeted treatments for acute and chronic pain, primarily through its three commercialized products: ZTlido (lidocaine topical system), ELYXYB (celecoxib oral solution), and GLOPERBA (colchicine oral solution). Its primary business segments are categorized by therapeutic delivery, including topical systems, oral solutions, and a late-stage pipeline of injectable corticosteroids like SP-102 (SEMDEXA) for sciatica. Scilex competes directly with specialty pharmaceutical firms such as Neurogene (NGNE), Minerva Neurosciences (NERV), Aardvark Therapeutics (AARD), and Lifecore Biomedical (LFCR). Within this landscape, Scilex differentiates itself by focusing exclusively on non-addictive, non-opioid alternatives, positioning itself as a leader in the transition away from opioid-based pain management protocols. Leadership is currently headed by Henry Ji, Ph.D., who serves as Executive Chairman, CEO, and President following his appointment in August 2025; Dr. Ji is a prominent industry figure who co-founded Sorrento Therapeutics and Vivasor Inc. The executive team includes Stephen Ma, who holds the dual roles of Chief Operating Officer and Chief Financial Officer, and Suketu D. Desai, Ph.D., who serves as Chief Technology Officer and Senior Vice President of R&D. Commercial operations are led by Suresh K. Khemani (Chief Commercial Officer), while Gigi DeGuzman serves as Chief of Staff and Vice President of Administrative Operations. The company’s board of directors features notable industry veterans including former CEO Jaisim Shah, Dorman Followwill, and Dr. Yue Alexander Wu. Scilex maintains a significant institutional investor base, with major holdings from Armistice Capital LLC, The Vanguard Group, and BlackRock, reflecting its status as a key player in the specialty pain management sector.